Therapeutic Strategies in Children with Epilepsy: A Quality-of-Life-Related Perspective

Hideaki Kanemura1

  • 1Department of Pediatrics, Toho University Medical Center Sakura Hospital, 564-1 Shimoshizu, Sakura 285-8741, Chiba, Japan.

PubMed

Insights

Seizure severity and EEG abnormalities significantly impact children's quality of life. Early therapeutic management targeting both seizures and interictal epileptiform discharges (IEDs) is crucial for improving outcomes in childhood epilepsy.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Neuroscience

Background:

  • Childhood epilepsy affects quality of life (QOL) through clinical and social factors.
  • Seizure severity, frequent seizures, and status epilepticus (SE) are key QOL predictors.
  • Interictal epileptiform discharges (IEDs) on EEG may also predict QOL by causing cognitive and behavioral issues.

Purpose of the Study:

  • To investigate the relationship between seizure severity, EEG abnormalities, and QOL in children with epilepsy.
  • To explore the role of IEDs, particularly frontal IEDs and secondary bilateral synchrony (SBS), in neuropsychological impairments.
  • To identify therapeutic strategies for improving QOL by managing seizures and EEG abnormalities.

Main Methods:

  • Analysis of clinical data including seizure severity and frequency.
  • Electroencephalogram (EEG) evaluation for interictal epileptiform discharges (IEDs) and secondary bilateral synchrony (SBS).
  • Assessment of cognitive and behavioral disturbances as indicators of neuropsychological impairment.

Main Results:

  • Seizure severity and IEDs are linked to neuropsychological impairments and reduced QOL.
  • Frontal IEDs and SBS are associated with cognitive decline and behavioral disturbances.
  • Novel antiseizure medications (ASMs) like levetiracetam and perampanel show potential in suppressing both seizures and IEDs.

Conclusions:

  • Reducing seizure severity and EEG abnormalities (frontal IEDs, SBS) is essential for enhancing QOL in pediatric epilepsy.
  • Strategic ASM selection, including novel agents, can effectively manage both clinical seizures and EEG abnormalities.
  • Early and comprehensive therapeutic interventions are vital for improving long-term outcomes in children with epilepsy.

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
190
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
41
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
304
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
405
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
183
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
406